Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287793 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01287793 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants.
The verdict
NCT01287793, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.
Interventions
- DRUG placebo
- DRUG moxifloxacin
- DRUG tigecycline
- DRUG 100 mL 0.9% Sodium Chloride intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287793
The ClinicalTrials.gov registry entry for NCT01287793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01287793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287793 about?
NCT01287793 is a clinical study titled "Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects". Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.
What is the current status of trial NCT01287793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01287793?
The interventions under investigation include: placebo (DRUG), moxifloxacin (DRUG), tigecycline (DRUG), 100 mL 0.9% Sodium Chloride intravenous (DRUG).
Who is sponsoring clinical trial NCT01287793?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.